843643-03-8

Basic information

• Product Name: 2-(6-aminopyridin-3-yl)propan-2-ol
• Synonyms: 2-(6-aminopyridin-3-yl)propan-2-ol;2-(6-Amino-3-pyridyl)propan-2-ol;2-Amino-5-(1-hydroxy-1-methylethyl)pyridine;6-Amino-alpha,alpha-dimethyl-3-pyridinemethanol;2-(6-Amino-pyridin-3-yl)-propan-2-ol（WS202218）
• CAS NO: 843643-03-8
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19368
• Mol File: 843643-03-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(6-aminopyridin-3-yl)propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-aminopyridin-3-yl)propan-2-ol(843643-03-8)
• EPA Substance Registry System: 2-(6-aminopyridin-3-yl)propan-2-ol(843643-03-8)

Safety Data

• Hazardous Substances Data: 843643-03-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(6-aminopyridin-3-yl)propan-2-ol is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into various drug molecules, enhancing their therapeutic properties.
Used in Organic Synthesis:
In the field of organic chemistry, 2-(6-aminopyridin-3-yl)propan-2-ol is used as a building block for the creation of more complex organic compounds, contributing to the development of new materials and chemical entities.
Used in Cancer Treatment:
2-(6-aminopyridin-3-yl)propan-2-ol is used as a potential anti-cancer agent for its ability to inhibit the growth of cancer cells, offering a new avenue for cancer treatment strategies.
Used in Neurodegenerative Disease Therapy:
2-(6-aminopyridin-3-yl)propan-2-ol is also being studied for its potential use as a therapeutic agent for neurodegenerative diseases, suggesting its possible role in managing or treating conditions like Alzheimer's or Parkinson's disease.

Upstream product

• 36052-24-1 methyl 6-aminonicotinoate 
• 917-54-4 methyllithium 
• 68700-91-4 2-chloro-5-(1-hydroxy-1-methylethyl)pyridine 
• 676-58-4 methylmagnesium chloride 
• 53939-30-3 5-bromo-2-chloropyridine 

Downstream Products

• 1000845-17-9 [6-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridin-2-yl](phenyl)methanone hydrobromide 
• 1000843-73-1 6-(1-hydroxy-1-methylethyl)-N-phenylimidazo[1,2-a]pyridine-2-carboxamide 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

SYK INHIBITOR AND USE METHOD THEREFOR

Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.

New tetrahydropyrido pyrimidinecarboxylic compound or salt thereof

To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention is related to a compound of formula (I) wherein R1, R2, R3, R4 and X are as defined herein, or an acid-addition salt thereof, its preparation and therapeutic use in the treatment or prevention of diseases involving the Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1 and HZF3.

DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS

The present invention is related to a compound of formula (I): wherein R1, R2, R3, R4 and X are as defined herein, or an addition salt with an acid thereof, its pharmaceutical composition or use for treating or preventing diseases involving Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1 and HZF3.